Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL

Blood Adv (2023) 7 (7): 1146–1155.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals